Brighton Collaboration Releases New Template for Evaluating VSV-Based Lassa Fever Vaccines
The Brighton Collaboration is proud to announce the publication of a new standardized template to support benefit-risk assessments for vesicular stomatitis virus (VSV) vector vaccines targeting Lassa fever. This tool is designed to enhance scientific consistency, transparency, and rigor in evaluating novel vaccine platforms.
🔗 Read the full article: ScienceDirect – Vaccine Journal
Lassa fever is an emerging infectious disease with increasing public health significance, particularly in West Africa. In response, global efforts are accelerating the development of innovative vaccines, including those using VSV vectors—platforms that have shown promise in other outbreak contexts.
This new template:
Offers a structured framework for benefit-risk assessment of VSV-based Lassa vaccines
Was developed with input from multidisciplinary global experts
Aligns with strategic priorities set by CEPI, WHO, and other global health bodies
Supports both scientific evaluation and policymaking for vaccine safety
The publication reflects Brighton Collaboration’s ongoing mission to foster vaccine safety, transparency, and harmonization of assessment tools across emerging platforms.
We invite researchers, developers, regulators, and public health stakeholders to use, adapt, and contribute to the continued refinement of this important resource.
📢 Feedback and collaboration are welcome.
Join us in strengthening vaccine safety science for Lassa fever and beyond.
Â
